PB2034: CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB-CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA. (23rd June 2022) - Vij, R.; Schade, H.; Trudel, S.; Chang, A. C.; Huang, J.; Samineni, D.; Sumiyoshi, T.; Tsai, J.; Wong, T.; Harrison, S. J.